Collegium Pharmaceutical

Collegium Pharmaceutical

> Contact Information

Collegium Pharmaceutical, Inc. (Nasdaq GS: COLL) is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for patients suffering from chronic pain.   Collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the Company’s proprietary DETERx® technology platform.  Collegium’s lead product candidate, Xtampza ER™, is an abuse-deterrent, extended-release, oral formulation of oxycodone, and is the first of a number of product candidates using the DETERx technology. Xtampza ER has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Collegium had its initial public offering in May, 2015.  It currently has a request before the FDA to convert its Tentative Approval for Xtampza ER  to a Final Approval.

 
Related News
Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
03.03.16
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-reviewed Journal of Opioid Management. The publication is titled, “In Vitro Assessment of the Potential for Abuse via the Intravenous Route of Oxycodone DETERx® Microspheres.” Read Full Release
BMP Portfolio Company Collegium Announces Favorable Judgment by the District Court of Massachusetts
02.11.16
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application for Xtampza™ ER... Read Full Release
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
11.09.15
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announces that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules. Read Full Release
Boston Millennia Portfolio Company, Collegium Pharmaceutical Raises $50 million Financing
03.10.15
Collegium Pharmaceutical, Inc., today announced that it has raised a $50 million financing. Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER through potential FDA approval and commercial launch as well as to fund operational growth and other pipeline development programs. Read Full Release
Millennia Portfolio Company, Collegium Pharmaceutical, Announces Positive Top-Line Data from Phase III Study of Oxycodone DETERx®
08.06.14
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced positive top-line results from its pivotal Phase 3 study of the company’s investigational analgesic Oxycodone DETERx® that studied the treatment of patients with moderate-to-severe chronic low back pain. Read Full Release
Boston Millennia Partners Congratulates PreCision Dermatology Management on $500 Million Sale to Valeant Pharmaceuticals International
07.07.14
With the receipt of Hart-Scott-Rodino clearance, the previously announced acquisition of Precision Dermatology by Valeant Pharmaceuticals International, Inc. for $500 million, closed July 7, 2014. Read Full Release
Millennia Portfolio Company, Collegium Pharmaceutical, Completes Successful IPO
05.12.14
Millennia Portfolio Company, Collegium Pharmaceutical Inc., a specialty pharmaceutical company developing abuse-deterrent products, announced the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share. (Nasdaq:COLL) Read Full Release
Boston Millennia Portfolio Company, Collegium Pharmaceutical, Featured in Wall Street Journal
05.06.13
Collegium Pharmaceutical was featured in a Wall Street Journal article discussing the innovative technologies being developed in the painkiller market to make drugs more abuse-deterrent. Read Full Release
Boston Millennia Partners Portfolio Company, Collegium Pharmaceuticals, Announces Successful Completion of Clinical Study
04.17.13
Millennia Portfolio Company, Collegium Pharmaceuticals, announced today the top-line results from its completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. Read Full Release